Cited by 88Advanced Glycation End Products researchChronic Kidney Disease and DiabetesPotato Plant Research

Kidney, heart and brain: three organs targeted by ageing and glycation

Frimat, Marie, Daroux, Maité, Litke, Rachel, Nevière, Rémi, Tessier, Frédéric J., Boulanger, Eric·2017·Clinical Science

Abstract

Advanced glycation end-product (AGE) is the generic term for a heterogeneous group of derivatives arising from a non-enzymatic reaction between reducing sugars and proteins. In recent years, evidence has accumulated that incriminates AGEs in pathogenic processes associated with both chronic hyperglycaemia and age-related diseases. Regardless of their exogenous or endogenous origin, the accumulation of AGEs and their derivatives could promote accelerated ageing by leading to protein modifications and activating several inflammatory signalling pathways via AGE-specific receptors. However, it remains to be demonstrated whether preventing the accumulation of AGEs and their effects is an important therapeutic option for successful ageing. The present review gives an overview of the current knowledge on the pathogenic role of AGEs by focusing on three AGE target organs: kidney, heart and brain. For each of these organs we concentrate on an age-related disease, each of which is a major public health issue: chronic kidney disease, heart dysfunction and neurodegenerative diseases. Even though strong connections have been highlighted between glycation and age-related pathogenesis, causal links still need to be validated. In each case, we report evidence and uncertainties suggested by animal or epidemiological studies on the possible link between pathogenesis and glycation in a chronic hyperglycaemic state, in the absence of diabetes, and with exogenous AGEs alone. Finally, we present some promising anti-AGE strategies that are currently being studied.

Integrity signals

Registry

Crossref · 10.1042/cs20160823

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The citation lists haven’t been fetched yet

References 250 · Cited by 88

Authors
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E.
Affiliations
  • Inserm (FR)
  • University of Lille, INSERM, CHU Lille, U995–LIRIC–Lille Inflammation Research International Centre, F-59000 Lille, France
Corresponding author
Frimat, Marie
Venue
Clinical Science
Published
2017-05-17
Volume
131
Issue
11
Pages
1069-1092
ISSN
  • 0143-5221 (ISSN-L)
  • 1470-8736
OpenAlex
W2614693007
Cited by
88
References
250
Citations by year
2026: 5 · 2025: 5 · 2024: 7 · 2023: 9 · 2022: 9 · 2021: 13 · 2020: 10 · 2019: 15 · 2018: 12 · 2017: 3
FWCI
1.47
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Science (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Potato Plant Research
Keywords
advanced glycation end products, glycation, aging, chronic hyperglycemia, chronic kidney disease, cardiac dysfunction, neurodegenerative diseases, AGE receptor, inflammation, protein modification
MeSH terms
Receptor for Advanced Glycation End Products, Aging, Diet, Glycosylation, Heart Diseases, Humans, Glycation End Products, Advanced, Neurodegenerative Diseases, Renal Insufficiency, Chronic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review